Effect of APC and Epo on the Inflammatory Response During Sepsis

An observational study to determine the effect of APC and Epo in reducing the systemic inflammatory response during severe sepsis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sepsis Infections Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms Shock Shock, Septic Systemic Inflammation Systemic Inflammatory Response Syndrome

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Lawson Health Research Institute

London, Ontario, N6A 4G5, Canada

About this study

An observational study to determine the effect of APC and Epo in reducing the systemic inflammatory response during severe sepsis. Patients already prescribed either drug will be enrolled. The microcirculation of the sublingual vascular bed will be observed with a microscope to detect the alterations in the inflammatory response.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients in the ICU in severe septic shock undergoing APC and/or Epo treatment

Exclusion criteria

any severe comorbid conditions

Sponsors and collaborators

Lead sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Other

Registry information

Official study title

Effect of Activated Protein C and Erythropoietin on the Microvascular Inflammatory Response During Severe Sepsis.

Important dates

Study start: 2005
Primary completion: 2010
Study completion: 2011
First posted: Sep 29, 2005
Registry last updated: Aug 25, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed